alexa ATMP Cell Therapy: Triumphs And Constraints For Unmet Clinical Needs
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

15th Annual Summit on Vaccines and Immunization
February 20-21, 2017 Berlin, Germany

Shreemanta K Parida
Justus-Liebig University, Germany
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.C1.054
Immunotherapy for Cancer, adjudged "Breakthrough of the year 2013" by journal "Science", was a paradigm shift and "game changer" in the conquest of cancer by targeting immune-system than the tumour. Cell therapy and immune therapy have opened up plethora of options to address unmet clinical needs with greater role in haemato-oncology field with promising clinical success in combating graft vs. host disease in transplant patients as well as in preventing infections in them. However, achieving the optimal numbers and the desired phenotypes of cells by conventional expansion culture methods have been major constraints. The increasing use of cell therapy towards myriads of clinical conditions has led to production processes in accordance with Good Manufacturing Practice (GMP) for Advanced Therapeutic Medicinal Product (ATMP). In cellular therapy, safety remains of paramount importance and refers to consistency, quality and potency, not only at the batch release level but also during the process development which should be adapted to closed systems that are easy to use. Implementing dynamic controls during the manufacturing of clinical-grade cells for therapy is essential to ensure microbiological safety and to avoid potential adverse effects linked to genomic instability driving transformation and senescence or decrease of cell functions (immunoregulation, differentiation potential). To meet this growing need of producing required cells of choice in bulk from bone marrow, peripheral blood or other tissues consistently in quality and numbers in a controlled, reproducible, robust, and efficient dynamic environment, tools and technologies have evolved offering in the form of GMP certified closed system at affordable cost to advance cell therapy into practice for the unmet clinical needs. We are at an interesting crossroad to push the limits making it accessible for the best outcomes for patients in precision medicine by validating tools and technologies as well as performing robustly designed clinical trials as way forward.

Shreemanta Parida is a Clinician Scientist with his expertise and passion in making a difference to patients by applying cross cutting scientific advances in patient care. He has been engaged during last 5 years in bringing ATMP cell therapy to translation in precision medicine for many unmet clinical needs. He has contributed immensely to the field of Global Health, Vaccines and Immunology over last three decades with focus on resource poor settings embracing stakeholders across disciplines. He has held many leadership positions in many top institutions in Europe, Africa and India.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version